Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 676-681

  Jeske, Stephanie ^a   Tagawa, Scott T ^a   Olowokure, Olugbenga ^b   Selzer, Jodi ^a   Giannakakou, Paraskevi ^a   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Castrate resistant; Chemotherapy; Docetaxel; Metastatic; Paclitaxel; Prostate cancer

Indexed keywords

BICALUTAMIDE; CARBOPLATIN; DOCETAXEL; ESTRADIOL; FLUTAMIDE; KETOCONAZOLE; NILUTAMIDE; PACLITAXEL;

ACRODYNIA; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORCHIECTOMY; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TAXOIDS;

EID: 81055131780     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.023     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Tannock I., Osoba D., Stockler M., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
3. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
4. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
5. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
6. Canobbio L., Guarneri D., Miglietta L., et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993, 29A:2094-2096.
7. Sternberg C.N., Petrylak D., Witjes F., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. J Clin Oncol 2007, 25:5019. (Meeting Abstracts).
8. Nakabayashi M., Sartor O., Jacobus S., et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU International 2008, 101:308-312.
9. Flaig T.W., Barqawi A., Miller G., et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006, 107:266-274.
10. Cabrespine A., Guy L., Khenifar E., et al. Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 2006, 67:354-359.
11. Kelly W.K., Curley T., Slovin S., et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001, 19:44-53.
12. Berry W., Friedland D., Fleagle J., et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006, 5:131-137.
13. Oh W.K., Hagmann E., Manola J., et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005, 11:284-289.
14. Oh W.K., Halabi S., Kelly W.K., et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer 2003, 98:2592-2598.
15. Ross R.W., Beer T.M., Jacobus S., et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008, 112:521-526.
16. Solit D.B., Morris M., Slovin S., et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003, 98:1842-1848.
17. Urakami S., Igawa M., Kikuno N., et al. Combination chemotherapy with paclitaxel, estramustine, and carboplatin for hormone refractory prostate cancer. J Urol 2002, 168:2444-2450.
18. Mathew P., DiPaola R. Taxane refractory prostate cancer. J Urol 2007, 178:S36-S41.
19. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials working group. J Clin Oncol 2008, 26:1148-1159.
20. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Cancer 2007, 110:556-563.
21. Loriot Y., Massard C., Gross-Goupil M., et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: A prospective study evaluating also neuroendocrine features. Ann Oncol 2009, 20:703-708.
22. Kaplan E., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-481.
23. Sternberg C., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005, 68:2-9.
24. Valero V., Jones S., Von Hoff D., et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998, 16:3362-3368.
25. Taguchi T., Aihara T., Takatsuka Y., et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 2004, 10:509-513.
26. Seidman A., Hochhauser D., Gollub M., et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996, 14:1877-1884.
27. Giannakakou P., Sackett D.L., Kang Y.-K., et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118-17125.
28. Giannakakou P., Gussio R., Nogales E., et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. PNAS 2000, 97:2904-2909.
29. Giannakakou P., Snyder J.P. Resistance to Microtubule-Targeting Drugs. Cancer drug discovery and development: Microtubule targets in cancer therapy 2008, 357-394. Humana Press Inc., Totowa, NJ. A.T. Fojo (Ed.).
30. Snyder J.P., Nettles J.H., Cornett B., et al. The binding conformation of taxol in β-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001, 98:5312-5316.
31. Thall P.F., Logothetis C., Pagliaro L.C., et al. Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J Natl Cancer Inst 2007, 99:1613-1622.
32. Machiels J.-P., Mazzeo F., Clausse M., et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008, 26:5261-5268.
33. Danila D.C., Rathkopf D.E., Morris M.J., et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol 2008, 26:5019. [Abstract].
34. Reid A.H., Attard G., Danila D.C., et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 2009, 27:5047. [Abstract].